Philadelphia is poised to launch the nation’s first city-sponsored retirement plan for workers whose employers don’t offer them. Voters on Tuesday sanctioned the city council’s PhillySaves program by ...

Update: Due to scheduling conflict, NJ.com will no longer be broadcasting the Prep B final at Diamond Nation on Thursday afternoon. Two of the top baseball prep programs in the state will meet on ...

Julia is the associate news editor for Health, where she edits and publishes news articles on trending health and wellness topics. Her work has been featured in The Heights, an independent student ...

Veronica Beagle is the managing editor for Education at Forbes Advisor. She completed her master’s in English at the University of Hawai‘i at Mānoa. Before coming to Forbes Advisor she worked on ...

Veronica Beagle is the managing editor for Education at Forbes Advisor. She completed her master’s in English at the University of Hawai‘i at Mānoa. Before coming to Forbes Advisor she worked on ...

Samantha (Sam) Silberstein, CFP®, CSLP®, EA, is an experienced financial consultant. She has a demonstrated history of working in both institutional and retail environments, from broker-dealers to ...

A free three-week virtual course designed to help aspiring and early-stage entrepreneurs begin building a startup. Participants connect with peers, experienced founders and resource providers across ...

Expanding child care is a pillar of Mayor Zohran Mamdani’s affordability agenda. Newly released application numbers may raise questions about strategy and demand. By Eliza Shapiro and Matthew Haag See ...

Peter is a managing editor for the CNET Group. He has been covering technology, software, finance, sports and video games since working for @Home Network and Excite in the 1990s. Peter managed reviews ...

It’s time for a new way of thinking. by Robin J. Ely and David A. Thomas “The business case has been made to demonstrate the value a diverse board brings to the company and its constituents.” Robin J.

Eli Lilly looks set to extend the reach of its RET inhibitor Retevmo in RET-mutated tumours, as the LIBRETTO-432 trial shows its value in an adjuvant lung cancer setting. The LIBRETTO-432 trial showed ...